Kyowa Kirin Past Earnings Performance

Past criteria checks 5/6

Kyowa Kirin has been growing earnings at an average annual rate of 12.2%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 7% per year. Kyowa Kirin's return on equity is 9.8%, and it has net margins of 18.3%.

Key information

12.2%

Earnings growth rate

12.3%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate7.0%
Return on equity9.8%
Net Margin18.3%
Next Earnings Update01 Aug 2024

Recent past performance updates

Recent updates

Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Jul 11
Kyowa Kirin Co., Ltd.'s (TSE:4151) Share Price Could Signal Some Risk

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Jun 19
Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Jun 14
Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09
Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Apr 25
Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Apr 11
Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Mar 19
Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Feb 27
Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Revenue & Expenses Breakdown

How Kyowa Kirin makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4151 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 24454,26783,060161,46378,803
31 Dec 23442,23381,188163,07872,106
30 Sep 23420,64957,915158,13869,927
30 Jun 23412,30940,202162,07768,639
31 Mar 23404,15550,295161,79665,906
31 Dec 22398,37153,573166,18562,896
30 Sep 22382,05268,651148,26561,591
30 Jun 22372,49662,292144,30759,093
31 Mar 22358,88255,464139,53959,095
31 Dec 21352,24652,347135,10557,679
30 Sep 21338,31742,446132,49555,518
30 Jun 21325,55444,301125,53754,739
31 Mar 21322,17446,106118,47452,705
31 Dec 20318,35247,027116,52552,312
30 Sep 20314,36748,255110,49852,674
30 Jun 20312,22346,819109,17252,702
31 Mar 20307,27842,212109,27553,393
31 Dec 19305,82037,674106,24553,511
30 Sep 19374,26738,519121,87154,203
30 Jun 19325,82738,796107,90950,395
31 Mar 19337,64541,713108,97249,594
31 Dec 18346,53154,414110,28348,591
30 Sep 18292,66265,95395,51245,242
30 Jun 18349,81563,500108,09347,611
31 Mar 18347,16656,420106,32148,301
31 Dec 17353,38042,899104,60849,155
30 Sep 17343,69721,949101,40751,146
30 Jun 17344,64821,576100,09051,138
31 Mar 17345,48519,754100,66651,855
31 Dec 16343,01918,669100,62153,792
30 Sep 16349,13420,199103,03854,156
30 Jun 16359,53531,014104,85254,670
31 Mar 16363,18732,566104,81853,096
31 Dec 15364,31629,774105,70251,518
30 Sep 15367,45329,906104,17451,343
30 Jun 15350,38416,236103,16349,892
31 Mar 15336,96514,173101,05449,442
31 Dec 14333,44615,89899,39647,667
30 Sep 14327,44418,791100,05045,405
30 Jun 14332,80321,58598,60344,541
31 Mar 14340,09026,01085,67453,986
31 Dec 13340,61130,07898,03743,633
30 Sep 13340,57032,08297,37041,873

Quality Earnings: 4151 has high quality earnings.

Growing Profit Margin: 4151's current net profit margins (18.3%) are higher than last year (12.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4151's earnings have grown by 12.2% per year over the past 5 years.

Accelerating Growth: 4151's earnings growth over the past year (65.1%) exceeds its 5-year average (12.2% per year).

Earnings vs Industry: 4151 earnings growth over the past year (65.1%) exceeded the Pharmaceuticals industry 12.7%.


Return on Equity

High ROE: 4151's Return on Equity (9.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.